GP 1a

CAS No. 511532-96-0

GP 1a( —— )

Catalog No. M35265 CAS No. 511532-96-0

GP 1a is a potent agonist of cannabinoid receptor 2 (CB2) (EC50=7.1), as shown in cAMP, GTPγS and β-arrestin recruitment assays.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 107 In Stock
10MG 169 In Stock
25MG 341 In Stock
50MG 496 In Stock
100MG 706 In Stock
200MG Get Quote In Stock
500MG 1423 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    GP 1a
  • Note
    Research use only, not for human use.
  • Brief Description
    GP 1a is a potent agonist of cannabinoid receptor 2 (CB2) (EC50=7.1), as shown in cAMP, GTPγS and β-arrestin recruitment assays.
  • Description
    GP1a is a potent agonist of cannabinoid receptor 2 (CB2). Gp1a is beneficial to skin wound healing. GP1a inhibits inflammation and fibrogenesis while promoting re-epithelialization.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    Cannabinoid Receptor
  • Recptor
    Cannabinoid Receptor | PERK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    511532-96-0
  • Formula Weight
    441.35
  • Molecular Formula
    C23H22Cl2N4O
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 125 mg/mL (283.22 mM; Ultrasonic )
  • SMILES
    C(NN1CCCCC1)(=O)C=2C3=C(N(N2)C4=C(Cl)C=C(Cl)C=C4)C=5C(C3)=CC(C)=CC5
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Zhao C, et al. An enzyme-responsive Gp1a-hydrogel for skin wound healing. J Biomater Appl. 2021;36(4):714-721.?
molnova catalog
related products
  • CB2R/FAAH modulator-...

    CB2R/FAAH modulator-3 (compound 27) is a modulator targeting CB2R and FAAH, acting as a CB2R agonist with a Ki value of 20.1 nM and a CB1R agonist with a Ki value of 67.6 nM, while inhibiting FAAH with an IC50 value of 3.4 μM.

  • GAT-211

    GAT-211 (GAT211) is a selective cannabinoid 1 receptor (CB1R) positive allosteric modulator with pKb of 7.26, Arrestin2 EC50 of 775 nM.

  • CB1 antagonist 2

    CB1 antagonist 2 is caimabinoid 1 (CB1) antagonist extracted from patent WO2016184310A1, compound 3. Which inhibits CB1 in vivo with an IC50 of 25.5 nM.